Zhang S W, Yang Z X, Zheng R S, Zeng H M, Chen W Q, He J
National Office for Cancer Prevention and Control, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Department of Thoracic Surgery, National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2017 Jul 23;39(7):547-552. doi: 10.3760/cma.j.issn.0253-3766.2017.07.015.
To estimate the incidence and mortality of stomach cancer in China based on the cancer registration data in 2013, collected by the National Central Cancer Registry (NCCR). There were 347 cancer registries that submitted stomach cancer incidence and deaths occurred in 2013 to NCCR. After evaluating the data quality, 255 registries' data were accepted for analysis and stratified by areas (urban/rural), sex, and age group. Combined with data on national population in 2013, the nationwide incidence and mortality of stomach cancer were estimated. Chinese population census in 2000 and Segi's population were used for age-standardized incidence/mortality rates. Qualified 255 cancer registries covered a total of 226 494 490 populations (111 595 772 in urban and 114 898 718 in rural areas). The percentage of cases morphologically verified and death certificate-only cases were 76.27% and 1.98%, respectively, and the mortality to incidence rate ratio was 0.72. It is estimated that there were 427 000 new cases for stomach cancer nationwide, with a crude incidence rate of 31.38 per 100 000 (42.85 per 100 000 in males, 19.33 per 100 000 in females). The age-standardized incidence rates by Chinese standard population (ASR China) and by world standard population (ASR world) were 21.40 per 100 000 and 21.32 per 100 000, respectively, with a cumulative incidence rate (0-74 age years old) of 2.66%. The crude and ASR China incidence rates of stomach cancer in urban areas were 27.80 per 100 000 and 18.48 per 100 000, respectively, whereas those were 35.54 per 100 000 and 24.93 per 100 000 in rural areas. It is estimated that there were 301 000 deaths for stomach cancer nationwide, with a crude mortality rate of 22.13 per 100 000 (29.85 per 100 000 in males, 14.03 per 100 000 in females). The ASR China and ASR world mortality rates were 14.68 per 100 000 and 14.54 per 100 000, respectively, with a cumulative mortality rate (0-74 years old) of 1.70%. The crude and ASR China mortality rates were 18.94 per 100 000 and 12.20 per 100 000 in urban areas, respectively, whereas those were 25.84 per 100 000 and 17.67 per 100 000 in rural areas. There is still a heavy burden of stomach cancer in China. The burden and patterns of stomach cancer shows different gender and urban-rural differences. Prevention and control strategies should be implemented referring to local status.
基于国家癌症中心(NCCR)收集的2013年癌症登记数据,估算中国胃癌的发病率和死亡率。共有347个癌症登记处向NCCR提交了2013年发生的胃癌发病和死亡数据。在评估数据质量后,接受了255个登记处的数据用于分析,并按地区(城市/农村)、性别和年龄组进行分层。结合2013年全国人口数据,估算了全国胃癌的发病率和死亡率。采用2000年中国人口普查数据和Segi人口数据计算年龄标准化发病率/死亡率。符合条件的255个癌症登记处覆盖总人口226494490人(城市111595772人,农村114898718人)。形态学确诊病例的比例和仅依据死亡证明的病例比例分别为76.27%和1.98%,死亡率与发病率之比为0.72。据估计,全国胃癌新发病例42.7万例,粗发病率为31.38/10万(男性为42.85/10万,女性为19.33/10万)。按中国标准人口计算的年龄标准化发病率(ASR China)和按世界标准人口计算的年龄标准化发病率(ASR world)分别为21.40/10万和21.32/10万,累积发病率(0至74岁)为2.66%。城市地区胃癌的粗发病率和ASR China发病率分别为27.80/10万和18.48/10万,而农村地区分别为35.54/10万和24.93/10万。据估计,全国胃癌死亡病例30.1万例,粗死亡率为22.13/10万(男性为29.85/10万,女性为14.03/10万)。ASR China和ASR world死亡率分别为14.68/10万和14.54/10万,累积死亡率(0至74岁)为1.70%。城市地区胃癌的粗死亡率和ASR China死亡率分别为18.94/10万和12.20/10万,而农村地区分别为25.84/10万和17.67/10万。中国胃癌负担仍然沉重。胃癌的负担和模式存在不同的性别差异和城乡差异。应参照当地情况实施防控策略。
Zhonghua Zhong Liu Za Zhi. 2017-7-23
Zhonghua Zhong Liu Za Zhi. 2018-9-23
Zhonghua Liu Xing Bing Xue Za Zhi. 2018-10-10
Zhonghua Zhong Liu Za Zhi. 2018-4-23
Zhonghua Zhong Liu Za Zhi. 2018-3-23
Zhonghua Zhong Liu Za Zhi. 2019-1-23
Zhonghua Zhong Liu Za Zhi. 2023-3-23
Zhonghua Zhong Liu Za Zhi. 2019-10-23
Zhonghua Zhong Liu Za Zhi. 2018-12-23
Zhonghua Zhong Liu Za Zhi. 2017-1-23
Cancer Commun (Lond). 2019-5-2
J Surg Oncol. 2018-11